{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"submitter":["Hailemichael Y"],"funding":["UT MD Anderson Cancer Center SPORE in Melanoma grant from NCI","NA","NIAID NIH HHS","NCI NIH HHS","Cancer Prevention and Research Institute of Texas"],"pagination":["1338-1354"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC5873868"],"repository":["biostudies-literature"],"omics_type":["Unknown"],"volume":["128(4)"],"pubmed_abstract":["Anticancer vaccination is a promising approach to increase the efficacy of cytotoxic T lymphocyte-associated protein 4 (CTLA-4) and programmed death ligand 1 (PD-L1) checkpoint blockade therapies. However, the landmark FDA registration trial for anti-CTLA-4 therapy (ipilimumab) revealed a complete lack of benefit of adding vaccination with gp100 peptide formulated in incomplete Freund's adjuvant (IFA). Here, using a mouse model of melanoma, we found that gp100 vaccination induced gp100-specific effector T cells (Teffs), which dominantly forced trafficking of anti-CTLA-4-induced, non-gp100-specific Teffs away from the tumor, reducing tumor control. The inflamed vaccination site subsequently also sequestered and destroyed anti-CTLA-4-induced Teffs with specificities for tumor antigens other "],"journal":["The Journal of clinical investigation"],"pubmed_title":["Cancer vaccine formulation dictates synergy with CTLA-4 and PD-L1 checkpoint blockade therapy."],"pmcid":["PMC5873868"],"funding_grant_id":["NA","RP140522","P50 CA093459","T32 AI007496","P30 CA044579"],"pubmed_authors":["Fu T","Sharma P","Hasan F","Xiao Z","Khong H","Hailemichael Y","Roszik J","Schluns KS","Vianden C","He Q","Anthony SM","Dai Z","Sharma M","Woods A","Nielsen MC","Overwijk WW","Singh M","Engelhard VH","Faak F","Moore D"],"additional_accession":[]},"is_claimable":false,"name":"Cancer vaccine formulation dictates synergy with CTLA-4 and PD-L1 checkpoint blockade therapy.","description":"Anticancer vaccination is a promising approach to increase the efficacy of cytotoxic T lymphocyte-associated protein 4 (CTLA-4) and programmed death ligand 1 (PD-L1) checkpoint blockade therapies. However, the landmark FDA registration trial for anti-CTLA-4 therapy (ipilimumab) revealed a complete lack of benefit of adding vaccination with gp100 peptide formulated in incomplete Freund's adjuvant (IFA). Here, using a mouse model of melanoma, we found that gp100 vaccination induced gp100-specific effector T cells (Teffs), which dominantly forced trafficking of anti-CTLA-4-induced, non-gp100-specific Teffs away from the tumor, reducing tumor control. The inflamed vaccination site subsequently also sequestered and destroyed anti-CTLA-4-induced Teffs with specificities for tumor antigens other ","dates":{"release":"2018-01-01T00:00:00Z","publication":"2018 Apr","modification":"2026-05-05T23:35:01.296Z","creation":"2019-03-26T23:44:12Z"},"accession":"S-EPMC5873868","cross_references":{"pubmed":["29480817"],"doi":["10.1172/jci93303","10.1172/JCI93303"]}}